Howard J Federoff

List of Publications by Year
in descending order

211 papers	15,581 citations	17405 63 h-index	18606 119 g-index
213 all docs	213 docs citations	213 times ranked	19191 citing authors

#	Article	IF	Citations
1	Mediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing Factor. Science, 2002, 297, 259-263.	6.0	1,671
2	Plasma phospholipids identify antecedent memory impairment in older adults. Nature Medicine, 2014, 20, 415-418.	15.2	885
3	PGC-1 Î±, A Potential Therapeutic Target for Early Intervention in Parkinsonâ€™s Disease. Science Translational Medicine, 2010, 2, 52ra73.	5.8	691
4	Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A caseâ€control study. Alzheimer's and Dementia, 2015, 11, 600.	0.4	656
5	Regulation of Neuronal Traits by a Novel Transcriptional Complex. Neuron, 2001, 31, 353-365.	3.8	400
6	Synuclein activates microglia in a model of Parkinson's disease. Neurobiology of Aging, 2008, 29, 1690-1701.	1.5	397
7	Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nature Medicine, 2010, 16, 998-1000.	15.2	342
8	Regulated Release and Polarized Localization of Brain-Derived Neurotrophic Factor in Hippocampal Neurons. Molecular and Cellular Neurosciences, 1996, 7, 222-238.	1.0	319
9	Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Research, 1994, 634, 7-12.	1.1	289
10	Expression of bcl-2 From a Defective Herpes Simplex Virusâ€“1 Vector Limits Neuronal Death in Focal Cerebral Ischemia. Stroke, 1995, 26, 1670-1675.	1.0	268
11	Apoptosis-Inducing Factor Substitutes for Caspase Executioners in NMDA-Triggered Excitotoxic Neuronal Death. Journal of Neuroscience, 2004, 24, 10963-10973.	1.7	258
12	Behavioral and Neurochemical Effects of Wild-Type and Mutated Human Î±-Synuclein in Transgenic Mice. Experimental Neurology, 2002, 175, 35-48.	2.0	255
13	Targeting Microglial Activation States as a Therapeutic Avenue in Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2017, 9, 176.	1.7	245
14	Modulation of the neuronal glutamate transporter EAAT4 by two interacting proteins. Nature, 2001, 410, 89-93.	13.7	234
15	Chronic Neuron-Specific Tumor Necrosis Factor-Alpha Expression Enhances the Local Inflammatory Environment Ultimately Leading to Neuronal Death in 3xTg-AD Mice. American Journal of Pathology, 2008, 173, 1768-1782.	1.9	205
16	Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. Lancet Neurology, The, 2015, 14, 1002-1009.	4.9	179
17	GAP-43 gene expression during development: persistence in a distinctive set of neurons in the mature central nervous system. Developmental Brain Research, 1989, 46, 161-168.	2.1	177
18	Hypoxia-Inducible Factor-1Î± Mediates Hypoxia-Induced Delayed Neuronal Death That Involves p53. Journal of Neuroscience, 1999, 19, 6818-6824.	1.7	175

#	Article	IF	Citations
19	Modules, networks and systems medicine for understanding disease and aiding diagnosis. Genome Medicine, 2014, 6, 82.	3.6	169
20	Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 6216-6221.	3.3	167
21	Oncolytic viral therapy for human colorectal cancer and liver metastases using a multiâ€mutated herpes simplex virus typeâ€1 (G207). FASEB Journal, 1999, 13, 1325-1334.	0.2	165
22	The Good, the Bad, and the Cell Type-Specific Roles of Hypoxia Inducible Factor-1Î± in Neurons and Astrocytes. Journal of Neuroscience, 2008, 28, 1988-1993.	1.7	154
23	Microglial Activation and Antioxidant Responses Induced by the Parkinsonâ€™s Disease Protein Î±-Synuclein. Journal of NeuroImmune Pharmacology, 2013, 8, 94-117.	2.1	145
24	Overexpression of NGF within the Heart of Transgenic Mice Causes Hyperinnervation, Cardiac Enlargement, and Hyperplasia of Ectopic Cells. Developmental Biology, 1995, 169, 309-321.	0.9	142
25	Mutant Î±-Synuclein Overexpression Mediates Early Proinflammatory Activity. Neurotoxicity Research, 2009, 16, 238-254.	1.3	130
26	HSV ICP0 recruits USP7 to modulate TLR-mediated innate response. Blood, 2009, 113, 3264-3275.	0.6	126
27	Blockade of Gap Junctions In Vivo Provides Neuroprotection After Perinatal Global Ischemia. Stroke, 2005, 36, 2232-2237.	1.0	121
28	Interventional MRI-guided Putaminal Delivery of AAV2-GDNF for a Planned Clinical Trial in Parkinson's Disease. Molecular Therapy, 2011, 19, 1048-1057.	3.7	120
29	Regeneration of the MPTP-Lesioned Dopaminergic System after Convection-Enhanced Delivery of AAV2-GDNF. Journal of Neuroscience, 2010, 30, 9567-9577.	1.7	113
30	The critical need for defining preclinical biomarkers in Alzheimer'sÂdisease. Alzheimer's and Dementia, 2014, 10, S196-212.	0.4	113
31	Positron emission tomography imaging for herpes virus infection: Implications for oncolytic viral treatments of cancer. Nature Medicine, 2001, 7, 859-863.	15.2	106
32	Lentivirus Vectors Using Human and Simian Immunodeficiency Virus Elements. Journal of Virology, 1999, 73, 2832-2840.	1.5	103
33	Safety Evaluation of AAV2-GDNF Gene Transfer into the Dopaminergic Nigrostriatal Pathway in Aged and Parkinsonian Rhesus Monkeys. Human Gene Therapy, 2009, 20, 1627-1640.	1.4	102
34	Neurotrophin-3 Transduction Attenuates Cisplatin Spiral Ganglion Neuron Ototoxicity in the Cochlea. Molecular Therapy, 2002, 6, 12-18.	3.7	101
35	Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease?. Molecular Brain Research, 2005, 134, 18-23.	2.5	100
36	Measuring the frequency of mouse and human cytotoxic T cells by the Lysispot assay: independent regulation of cytokine secretion and short-term killing. Nature Medicine, 2003, 9, 231-236.	15.2	99

#	Article	IF	Citations
37	Dysregulation of Gene Expression in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Mouse Substantia Nigra. Journal of Neuroscience, 2004, 24, 7445-7454.	1.7	98
38	Plasma 24-metabolite Panel Predicts Preclinical Transition to Clinical Stages of Alzheimerâ€™s Disease. Frontiers in Neurology, 2015, 6, 237.	1.1	97
39	PGCâˆ’1Î± Promoter Methylation in Parkinsonâ€™s Disease. PLoS ONE, 2015, 10, e0134087.	1.1	95
40	Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson's disease. Neurobiology of Disease, 2006, 21, 305-313.	2.1	92
41	ProlongedIn VivoGene Expression Driven by a Tyrosine Hydroxylase Promoter in a Defective Herpes Simplex Virus Amplicon Vector. Human Gene Therapy, 1996, 7, 2015-2024.	1.4	91
42	Immune Responses in Parkinsonâ€™s Disease: Interplay between Central and Peripheral Immune Systems. BioMed Research International, 2014, 2014, 1-9.	0.9	91
43	Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Therapy, 2002, 9, 935-945.	2.2	89
44	Selective Infection and Cytolysis of Human Head and Neck Squamous Cell Carcinoma with Sparing of Normal Mucosa by a Cytotoxic Herpes Simplex Virus Type 1 (G207). Human Gene Therapy, 1999, 10, 1599-1606.	1.4	86
45	Evolving From Reductionism to Holism. JAMA - Journal of the American Medical Association, 2009, 302, 994.	3.8	86
46	Functional Effects of AAV2-GDNF on the Dopaminergic Nigrostriatal Pathway in Parkinsonian Rhesus Monkeys. Human Gene Therapy, 2009, 20, 511-518.	1.4	86
47	p75 Neurotrophin Receptor Protects Primary Cultures of Human Neurons against Extracellular Amyloid Î² Peptide Cytotoxicity. Journal of Neuroscience, 2003, 23, 7385-7394.	1.7	83
48	HUMMR, a hypoxia- and HIF-1Î±â€“inducible protein, alters mitochondrial distribution and transport. Journal of Cell Biology, 2009, 185, 1065-1081.	2.3	81
49	Intravesical oncolytic viral therapy using attenuated, replicationâ€competent, herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model. FASEB Journal, 2001, 15, 1306-1308.	0.2	80
50	Precision pharmacology for Alzheimerâ€™s disease. Pharmacological Research, 2018, 130, 331-365.	3.1	79
51	Fetal Bovine Serum-Derived Extracellular Vesicles Persist within Vesicle-Depleted Culture Media. International Journal of Molecular Sciences, 2018, 19, 3538.	1.8	79
52	HSV Amplicon-Mediated Neurotrophin-3 Expression Protects Murine Spiral Ganglion Neurons from Cisplatin-Induced Damage. Molecular Therapy, 2001, 3, 958-963.	3.7	78
53	Clinically Relevant Effects of Convection-Enhanced Delivery of AAV2-GDNF on the Dopaminergic Nigrostriatal Pathway in Aged Rhesus Monkeys. Human Gene Therapy, 2009, 20, 497-510.	1.4	77
54	An improved method for generating consistent soluble amyloid-beta oligomer preparations for in vitro neurotoxicity studies. Journal of Neuroscience Methods, 2010, 190, 171-179.	1.3	76

#	Article	IF	Citations
55	Topical Application of Viral Vectors for Epidermal Gene Transfer. Journal of Investigative Dermatology, 1997, 108, 803-808.	0.3	75
56	Human Interleukin-10 Gene Transfer Is Protective in a Rat Model of Parkinson's Disease. Molecular Therapy, 2008, 16, 1392-1399.	3.7	75
57	What success can teach us about failure: the plasma metabolome of older adults with superior memory and lessons for Alzheimer's disease. Neurobiology of Aging, 2017, 51, 148-155.	1.5	74
58	Endothelin-1 regulates cardiac sympathetic innervation in the rodent heart by controlling nerve growth factor expression. Journal of Clinical Investigation, 2004, 113, 876-884.	3.9	74
59	Expression of thebcl-2Gene from a Defective HSV-1 Amplicon Vector Protects PancreaticÎ²-Cells from Apoptosis. Human Gene Therapy, 1996, 7, 1719-1726.	1.4	69
60	Expression of Vascular Endothelial Growth Factor From a Defective Herpes Simplex Virus Type 1 Amplicon Vector Induces Angiogenesis in Mice. Circulation Research, 1995, 76, 161-167.	2.0	68
61	A Novel Approach to Cancer Therapy Using an Oncolytic Herpes Virus to Package Amplicons Containing Cytokine Genes. Molecular Therapy, 2001, 4, 250-256.	3.7	66
62	Reporter Gene Transfer Induces Apoptosis in Primary Cortical Neurons. Molecular Therapy, 2002, 5, 723-730.	3.7	66
63	Visual deficits in a mouse model of Batten disease are the result of optic nerve degeneration and loss of dorsal lateral geniculate thalamic neurons. Neurobiology of Disease, 2006, 22, 284-293.	2.1	66
64	AÎ²-directed Single-chain Antibody Delivery Via a Serotype-1 AAV Vector Improves Learning Behavior and Pathology in Alzheimer's Disease Mice. Molecular Therapy, 2010, 18, 1471-1481.	3.7	66
65	Estrogenic regulation and sex dimorphism of growth-associated protein 43 kDa (GAP-43) messenger RNA in the rat. Molecular Brain Research, 1991, 11, 125-132.	2.5	65
66	Î±â€Synuclein mediates alterations in membrane conductance: a potential role for Î±â€synuclein oligomers in cell vulnerability. European Journal of Neuroscience, 2010, 32, 10-17.	1.2	65
67	Trial of magnetic resonanceâ€“guided putaminal gene therapy for advanced Parkinson's disease. Movement Disorders, 2019, 34, 1073-1078.	2.2	65
68	Helper-free HSV-1 amplicons elicit a markedly less robust innate immune response in the CNS. Molecular Therapy, 2003, 7, 218-227.	3.7	63
69	GDNF and Parkinsonâ€™s Disease: Where Next? A Summary from a Recent Workshop. Journal of Parkinson's Disease, 2020, 10, 875-891.	1.5	63
70	Herpes Simplex Virus Type 1 Amplicon Vectors with Glucocorticoid-Inducible Gene Expression. Human Gene Therapy, 1995, 6, 419-428.	1.4	61
71	Trk retrograde signaling requires persistent, Pincher-directed endosomes. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 852-857.	3.3	61
72	Transfer of the nerve growth factor gene into cell lines and cultured neurons using a defective Herpes Simplex virus vector. Transfer of the NGF gene into cells by a HSV-1 vector. Molecular Brain Research, 1994, 24, 327-335.	2.5	60

#	Article	IF	Citations
73	Expression of Human Immunodeficiency Virus Type 1 gp120 from Herpes Simplex Virus Type 1-Derived Amplicons Results in Potent, Specific, and Durable Cellular and Humoral Immune Responses. Journal of Virology, 2002, 76, 5565-5580.	1.5	60
74	CNS Delivery of Vectored Prion-specific Single-chain Antibodies Delays Disease Onset. Molecular Therapy, 2008, 16, 481-486.	3.7	60
75	Development of herpes simplex virus-1 ampliconâ€“based immunotherapy for chronic lymphocytic leukemia. Blood, 2001, 98, 287-295.	0.6	59
76	Combined delivery of Nogo-A antibody, neurotrophin-3 and the NMDA-NR2d subunit establishes a functional â€˜detourâ€™ in the hemisected spinal cord. European Journal of Neuroscience, 2011, 34, 1256-1267.	1.2	58
77	Neuronal Precursor-Restricted Transduction via in Utero CNS Gene Delivery of a Novel Bipartite HSV Amplicon/Transposase Hybrid Vector. Molecular Therapy, 2006, 13, 580-588.	3.7	57
78	Metabolomic biomarkers of pancreatic cancer: a meta-analysis study. Oncotarget, 2017, 8, 68899-68915.	0.8	55
79	The Endoplasmic Reticulum Stress Response Factor CHOP-10 Protects against Hypoxia-induced Neuronal Death. Journal of Biological Chemistry, 2010, 285, 21329-21340.	1.6	52
80	Localized gene transfer into organotypic hippocampal slice cultures and acute hippocampal slices. Journal of Neuroscience Methods, 1993, 50, 341-351.	1.3	51
81	Rapid Production of Interleukin-2-Secreting Tumor Cells by Herpes Simplex Virus-Mediated Gene Transfer: Implications for Autologous Vaccine Production. Human Gene Therapy, 1996, 7, 2217-2224.	1.4	50
82	Dendritic Cells Transduced with HSV-1 Amplicons Expressing Prostate-Specific Antigen Generate Antitumor Immunity in Mice. Human Gene Therapy, 2001, 12, 1867-1879.	1.4	50
83	Reduced Pathology and Improved Behavioral Performance in Alzheimer's Disease Mice Vaccinated With HSV Amplicons Expressing Amyloid-Î² and Interleukin-4. Molecular Therapy, 2008, 16, 845-853.	3.7	49
84	Alpha-Synuclein mRNA Is Not Increased in Sporadic PD and Alpha-Synuclein Accumulation Does Not Block GDNF Signaling in Parkinson's Disease and Disease Models. Molecular Therapy, 2017, 25, 2231-2235.	3.7	49
85	Ontogeny, sex dimorphism, and neonatal sex hormone determination of synapse-associated messenger RNAs in rat brain. Molecular Brain Research, 1993, 20, 101-110.	2.5	47
86	Antitumor efficacy of regional oncolytic viral therapy for peritoneally disseminated cancer. Journal of Molecular Medicine, 2000, 78, 166-174.	1.7	47
87	Convergent Pathobiologic Model of Parkinson's Disease. Annals of the New York Academy of Sciences, 2003, 991, 152-166.	1.8	46
88	Wild-type and mutant Î±-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD. Experimental Neurology, 2007, 204, 421-432.	2.0	46
89	Activity-dependent Î±-Cleavage of Nectin-1 Is Mediated by A Disintegrin and Metalloprotease 10 (ADAM10). Journal of Biological Chemistry, 2010, 285, 22919-22926.	1.6	46
90	Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurology, The, 2012, 11, 643-650.	4.9	46

#	Article	IF	Citations
91	Critical periods after stroke study: translating animal stroke recovery experiments into a clinical trial. Frontiers in Human Neuroscience, 2015, 9, 231.	1.0	46
92	Overexpression of GluR6 in Rat Hippocampus Produces Seizures and Spontaneous Nonsynaptic Bursting in Vitro. Neurobiology of Disease, 2000, 7, 362-374.	2.1	44
93	Human Dendritic Cells Transduced with Herpes Simplex Virus Amplicons Encoding Human Immunodeficiency Virus Type 1 (HIV-1) gp120 Elicit Adaptive Immune Responses from Human Cells Engrafted into NOD/SCID Mice and Confer Partial Protection against HIV-1 Challenge. Journal of Virology, 2005, 79, 2124-2132.	1.5	44
94	HSV amplicon-mediated AÎ² vaccination in Tg2576 mice: differential antigen-specific immune responses. Neurobiology of Aging, 2005, 26, 393-407.	1.5	44
95	Nerve growth factor somatic mosaicism produced by herpes virus-directed expression of ere recombinase. Nature Biotechnology, 1997, 15, 57-62.	9.4	43
96	Generating Differentially Targeted Amyloid-Î² Specific Intrabodies as a Passive Vaccination Strategy for Alzheimer's Disease. Molecular Therapy, 2009, 17, 2031-2040.	3.7	43
97	The role of the THY1 gene in human ovarian cancer suppression based on transfection studies. Cancer Genetics and Cytogenetics, 2004, 149, 1-10.	1.0	42
98	Viral Transduction of trkA into Cultured Nodose and Spinal Motor Neurons Conveys NGF Responsiveness. Developmental Biology, 1994, 163, 152-161.	0.9	41
99	Cloning and Characterization of the Rat Gene Encoding GAP-43. European Journal of Neuroscience, 1990, 2, 822-827.	1.2	40
100	Functional Interaction between Fluorodeoxyuridine-Induced Cellular Alterations and Replication of a Ribonucleotide Reductase-Negative Herpes Simplex Virus. Journal of Virology, 2001, 75, 7050-7058.	1.5	40
101	Reproducible and efficient murine CNS gene delivery using a microprocessor-controlled injector. Journal of Neuroscience Methods, 1998, 80, 137-147.	1.3	38
102	Altered Gene Expression Profiles Reveal Similarities and Differences Between Parkinson Disease and Model Systems. Neuroscientist, 2005, 11, 539-549.	2.6	38
103	Single-Chain Fragment Variable Passive Immunotherapies for Neurodegenerative Diseases. International Journal of Molecular Sciences, 2013, 14, 19109-19127.	1.8	37
104	Neurotrophin secretory pathways and synaptic plasticity. Neurobiology of Aging, 2003, 24, 1135-1145.	1.5	36
105	Î²-hexosaminidase lentiviral vectors: transfer into the CNS via systemic administration. Molecular Brain Research, 2005, 133, 286-298.	2.5	36
106	Proteolytic processing of proNGF is necessary for mature NGF regulated secretion from neurons. Biochemical and Biophysical Research Communications, 2007, 361, 599-604.	1.0	35
107	Temporal pattern of internucleosomal DNA fragmentation in the striatum and hippocampus after transient forebrain ischemia. Neuroscience Letters, 1995, 186, 157-160.	1.0	34
108	Viral Delivery of NR2D Subunits Reduces Mg2+ Block of NMDA Receptor and Restores NT-3-Induced Potentiation of AMPA-Kainate Responses in Maturing Rat Motoneurons. Journal of Neurophysiology, 2004, 92, 2394-2404.	0.9	34

#	Article	IF	Citations
109	Microarrays in Parkinsonâ€™s disease: A systematic approach. NeuroRx, 2006, 3, 319-326.	6.0	34
110	Future directions for immune modulation in neurodegenerative disorders: focus on Parkinsonâ€™s disease. Journal of Neural Transmission, 2010, 117, 1019-1025.	1.4	34
111	Personality and Performance in Specific Neurocognitive Domains Among Older Persons. American Journal of Geriatric Psychiatry, 2017, 25, 900-908.	0.6	34
112	Gene Therapy in the Inner Ear: Mechanisms and Clinical Implications. Annals of the New York Academy of Sciences, 1999, 884, 345-360.	1.8	31
113	Temporal and spatial localization of nectinâ€1 and lâ€afadin during synaptogenesis in hippocampal neurons. Journal of Comparative Neurology, 2008, 507, 1228-1244.	0.9	31
114	Identification of human Î±-synuclein specific single chain antibodies. Biochemical and Biophysical Research Communications, 2006, 349, 1198-1205.	1.0	30
115	Alterations in striatal dopamine catabolism precede loss of substantia nigra neurons in a mouse model of juvenile neuronal ceroid lipofuscinosis. Brain Research, 2007, 1162, 98-112.	1.1	30
116	Plasma metabolomic biomarkers accurately classify acute mild traumatic brain injury from controls. PLoS ONE, 2018, 13, e0195318.	1.1	30
117	Functional characterization of the rat GAP-43 promoter. Brain Research, 1994, 638, 211-220.	1.1	29
118	Neoadjuvant Interleukin-12 Immunogene Therapy Protects Against Cancer Recurrence After Liver Resection in an Animal Model. Annals of Surgery, 2000, 231, 762-771.	2.1	28
119	Utilizing Tumor Hypoxia to Enhance Oncolytic Viral Therapy in Colorectal Metastases. Annals of Surgery, 2004, 239, 892-902.	2.1	27
120	Loss of c/EBP-Î² activity promotes the adaptive to apoptotic switch in hypoxic cortical neurons. Molecular and Cellular Neurosciences, 2008, 38, 125-137.	1.0	27
121	A Neurotoxic Phosphoform of Elk-1 Associates with Inclusions from Multiple Neurodegenerative Diseases. PLoS ONE, 2010, 5, e9002.	1.1	26
122	Enhanced Learning in Mice Parallels Vector-Mediated Nerve Growth Factor Expression in Hippocampus. Human Gene Therapy, 2000, 11, 2341-2352.	1.4	25
123	In Cultured Astrocytes, p53 and MDM2 Do Not Alter Hypoxia-inducible Factor-1Î± Function Regardless of the Presence of DNA Damage. Journal of Biological Chemistry, 2007, 282, 16187-16201.	1.6	25
124	Genomics and Bioinformatics of Parkinson's Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a009449-a009449.	2.9	24
125	Repeated Acquisition and Performance Chamber for Mice: A Paradigm for Assessment of Spatial Learning and Memory. Neurobiology of Learning and Memory, 2000, 74, 241-258.	1.0	23
126	Efficacy of Multiagent Herpes Simplex Virus Amplicon-Mediated Immunotherapy as Adjuvant Treatment for Experimental Hepatic Cancer. Annals of Surgery, 2002, 236, 337-343.	2.1	23

#	Article	IF	Citations
127	Proteomic analysis of peripheral leukocytes in Alzheimer's disease patients treated with divalproex sodium. Neurobiology of Aging, 2008, 29, 1631-1643.	1.5	23
128	Glucocorticoid-Regulated VEGF Expression in Ischemic Skeletal Muscle. Molecular Therapy, 2002, 5, 300-306.	3.7	22
129	Systems healthcare: a holistic paradigm for tomorrow. BMC Systems Biology, 2017, 11, 142.	3.0	22
130	Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity. Cancer Research, 2002, 62, 6545-51.	0.4	22
131	Membrane palmitoylated proteins regulate trafficking and processing of nectins. European Journal of Cell Biology, 2011, 90, 365-375.	1.6	21
132	Ectodomain shedding of nectinâ€1 regulates the maintenance of dendritic spine density. Journal of Neurochemistry, 2012, 120, 741-751.	2.1	21
133	Herpes Simplex Virus Amplicon Delivery of a Hypoxia-Inducible Soluble Vascular Endothelial Growth Factor Receptor (sFlk-1) Inhibits Angiogenesis and Tumor Growth in Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2005, 12, 1025-1036.	0.7	20
134	Efficient gene transfer to human squamous cell carcinomas by the herpes simplex virus type 1 amplicon vector. American Journal of Surgery, 1998, 176, 404-408.	0.9	19
135	In vivo interleukin-2 gene therapy of established tumors with herpes simplex amplicon vectors. Cancer Immunology, Immunotherapy, 1999, 47, 265-271.	2.0	19
136	HSV Amplicon-Mediated Delivery of LIGHT Enhances the Antigen-Presenting Capacity of Chronic Lymphocytic Leukemia. Molecular Therapy, 2002, 6, 455-463.	3.7	18
137	Association of plasma YKL-40 with brain amyloid-Î² levels, memory performance, and sex in subjective memory complainers. Neurobiology of Aging, 2020, 96, 22-32.	1.5	18
138	Neuronal Specificity of HSV/Sleeping Beauty Amplicon Transduction In Utero Is Driven Primarily by Tropism and Cell Type Composition. Molecular Therapy, 2007, 15, 1848-1855.	3.7	17
139	Adoptively Transferred Tumor-Specific T Cells StimulatedEx vivoUsing Herpes Simplex Virus Amplicons Encoding 4-1BBL Persist in the Host and Show Antitumor ActivityIn vivo. Cancer Research, 2007, 67, 10027-10037.	0.4	17
140	Evaluation of an AAV2-Based Rapamycin-Regulated Glial Cell Line-Derived Neurotrophic Factor (GDNF) Expression Vector System. PLoS ONE, 2011, 6, e27728.	1.1	17
141	Plasma microRNA markers of upper limb recovery following human stroke. Scientific Reports, 2018, 8, 12558.	1.6	17
142	Translational considerations for CNS gene therapy. Expert Opinion on Biological Therapy, 2007, 7, 305-318.	1.4	16
143	Toward Reproducible Results from Targeted Metabolomic Studies: Perspectives for Data Pre-processing and a Basis for Analytic Pipeline Development. Current Topics in Medicinal Chemistry, 2018, 18, 883-895.	1.0	16
144	A Community-Based Study Identifying Metabolic Biomarkers of Mild Cognitive Impairment and Alzheimerâ€™s Disease Using Artificial Intelligence and Machine Learning. Journal of Alzheimer's Disease, 2020, 78, 1381-1392.	1.2	16

#	Article	IF	Citations
145	Enhanced vascularization and survival of neural transplants with ex vivo angiogenic gene transfer. Cell Transplantation, 2002, 11, 331-49.	1.2	16
146	Somatic gene transfer approaches to manipulate neural networks. Journal of Neuroscience Methods, 1997, 71, 133-142.	1.3	15
147	Efficient cotransduction of tumors by multiple herpes simplex vectors: Implications for tumor vaccine production. Cancer Gene Therapy, 2000, 7, 581-588.	2.2	15
148	Spatial And Temporal Expression of Herpes Simplex Virus Type 1 Amplicon-Encoded Genes: Implications for Their Use As Immunization Vectors. Human Gene Therapy, 2007, 18, 93-105.	1.4	15
149	Therapeutic potential of vaccines for Alzheimerâ€™s disease. Immunotherapy, 2011, 3, 287-298.	1.0	15
150	Perspectives on Best Practices for Gene Therapy Programs. Human Gene Therapy, 2015, 26, 127-133.	1.4	14
151	Potential Metabolomic Linkage in Blood between Parkinsonâ€™s Disease and Traumatic Brain Injury. Metabolites, 2018, 8, 50.	1.3	14
152	Identification of a Novel Nurr1-Interacting Protein. Journal of Neuroscience, 2008, 28, 9277-9286.	1.7	13
153	Characterization of nectin processing mediated by presenilinâ€dependent gammaâ€secretase. Journal of Neurochemistry, 2011, 119, 945-956.	2.1	13
154	CNS Gene Therapy and a Nexus of Complexity: Systems and Biology at a Crossroads. Cell Transplantation, 2006, 15, 267-273.	1.2	12
155	Effects of ex vivo transduction of mesencephalic reaggregates with bcl-2 on grafted dopamine neuron survival. Brain Research, 2007, 1134, 33-44.	1.1	12
156	Development of vaccination approaches for the treatment of neurological diseases. Journal of Comparative Neurology, 2009, 515, 4-14.	0.9	12
157	Gene Therapy: Charting a Future Courseâ€”Summary of a National Institutes of Health Workshop, April 12, 2013. Human Gene Therapy, 2014, 25, 488-497.	1.4	12
158	A retrotransposon storm marks clinical phenoconversion to late-onset Alzheimerâ€™s disease. GeroScience, 2022, 44, 1525-1550.	2.1	12
159	Herpes simplex virus amplicon delivery of a hypoxia-inducible angiogenic inhibitor blocks capillary formation in hepatocellular carcinoma. Journal of Gastrointestinal Surgery, 2004, 8, 812-823.	0.9	11
160	Nur(R1)turing a Notion on the Etiopathogenesis of Parkinsonâ€™s Disease. Neurotoxicity Research, 2009, 16, 261-270.	1.3	10
161	PU-91 drug rescues human age-related macular degeneration RPE cells; implications for AMD therapeutics. Aging, 2019, 11, 6691-6713.	1.4	10
162	HSV Amplicons: Neuro Applications. Current Gene Therapy, 2006, 6, 337-350.	0.9	9

#	Article	IF	Citations
163	Immune Responses to Herpesviral Vectors. Human Gene Therapy, 2009, 20, 434-441.	1.4	9
164	Disclosure of Clinical Trial Results When Product Development Is Abandoned. Science Translational Medicine, 2011, 3, 102cm29.	5.8	9
165	Plasma Sphingomyelins in Late-Onset Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 83, 1161-1171.	1.2	9
166	Seeking progress in disease modification in Parkinson disease. Parkinsonism and Related Disorders, 2021, 90, 134-141.	1.1	9
167	A role for mossy fiber activation in the loss of CA3 and hilar neurons induced by transduction of the GluR6 kainate receptor subunit. Neuroscience Letters, 1995, 191, 67-70.	1.0	8
168	Drug discovery dilemma and Cura Quartet collaboration. Drug Discovery Today, 2009, 14, 1006-1010.	3.2	8
169	Immune-Directed Gene Therapeutic Development for Alzheimerâ€™s, Prion, and Parkinsonâ€™s Diseases. Journal of NeuroImmune Pharmacology, 2009, 4, 298-308.	2.1	8
170	TGFÎ² Drives Metabolic Perturbations during Epithelial Mesenchymal Transition in Pancreatic Cancer: TGFÎ² Induced EMT in PDAC. Cancers, 2021, 13, 6204.	1.7	8
171	Gene therapeutic approaches to the treatment of Parkinson's disease. Clinical Neuroscience Research, 2001, 1, 483-495.	0.8	7
172	Systemic FIV vector administration: transduction of CNS immune cells and Purkinje neurons. Molecular Brain Research, 2003, 119, 1-9.	2.5	7
173	Gene Therapy for the Treatment of Parkinsonâ€™s Disease: The Nature of the Biologics Expands the Future Indications. Pharmaceuticals, 2012, 5, 553-590.	1.7	7
174	Biomarker validation: Methods and matrix matter. Alzheimer's and Dementia, 2017, 13, 608-609.	0.4	7
175	Luciferase: a sensitive and quantitative probe for blood-brain barrier disruption. Journal of Neuroscience Methods, 1998, 83, 159-164.	1.3	6
176	Focal hippocampal gain of NGF function elicits specific septal cholinergic reorganization. NeuroReport, 1999, 10, 337-344.	0.6	6
177	HSV Amplicon Transduction Activates an Innate Immune Response in CLL B Cells;Implications for Immune Therapy and Vaccine Development.. Blood, 2004, 104, 2514-2514.	0.6	6
178	Use of the herpes amplicon system as a vehicle for somatic gene transfer. Advanced Drug Delivery Reviews, 1997, 27, 29-39.	6.6	5
179	A New Research and Development Policy Framework for the Biomedical Research Enterprise. JAMA - Journal of the American Medical Association, 2010, 304, 1003.	3.8	5
180	Apolipoprotein E genotype impact on memory and attention in older persons: the moderating role of personality phenotype. International Journal of Geriatric Psychiatry, 2018, 33, 332-339.	1.3	5

#	Article	IF	Citations
181	Immune Shaping and the Development of Alzheimer's Disease Vaccines. Science of Aging Knowledge Environment: SAGE KE, 2005, 2005, pe35-pe35.	0.9	5
182	Effects of Herpes Simplex Virus Amplicon Transduction on Murine Dendritic Cells. Human Gene Therapy, 2009, 20, 442-452.	1.4	4
183	Development of Inducible Leucine-rich Repeat Kinase 2 (LRRK2) Cell Lines for Therapeutics Development in Parkinson's Disease. Neurotherapeutics, 2013, 10, 840-851.	2.1	4
184	Effect of earlyâ€stage Alzheimer's disease on household financial outcomes. Health Economics (United) Tj ETQq0 0 0 rgBT /Overlock 10	0.8	4
185	Safety of viral vectors for neurological gene therapies. Current Opinion in Molecular Therapeutics, 2004, 6, 473-81.	2.8	4
186	Reversal of Misfolding: Prion Disease Behavioral and Physiological Impairments Recover following Postnatal Neuronal Deletion of the PrP Gene. Neuron, 2007, 53, 315-317.	3.8	3
187	Augmentation of anti-tumor responses of adoptively transferred CD8+T cells in the lymphopenic setting by HSV amplicon transduction. Cancer Immunology, Immunotherapy, 2008, 57, 663-675.	2.0	3
188	Expression pattern of NuIP gene in adult mouse brain. Brain Research, 2009, 1302, 42-53.	1.1	3
189	An infectious conspiracy: the case for HSV-1 and APOEÏµ4 in Alzheimerâ€™s disease. Neurobiology of Aging, 1999, 20, 467-468.	1.5	2
190	Infectivity of herpes simplex virus type-1 (HSV-1) amplicon vectors in dendritic cells is determined by the helper virus strain used for packaging. Journal of Virological Methods, 2007, 145, 37-46.	1.0	2
191	Multidisciplinary Approaches to Biomedical Researchâ€”Reply. JAMA - Journal of the American Medical Association, 2010, 304, 2243.	3.8	2
192	The Evolution of Gene Transfer, Gene Therapy, and the RAC: IOM Recommendations to the NIH Director. Molecular Therapy, 2014, 22, 685-686.	3.7	2
193	Protect NIH's DNA advisory committee. Science, 2018, 362, 409-410.	6.0	2
194	Differential responses of AMD mitochondrial DNA haplogroups to PU-91, a mitochondria-targeting drug. Mitochondrion, 2021, 60, 189-200.	1.6	2
195	ANNOUNCING THE INAUGURAL ISSUE OF <I>TECHNOLOGY AND INNOVATION</I> (FORMERLY) Tj ETQq1 1 0.784314 rgBT /Overlock	0.2	1
196	Social media communications networks and pharmacovigilance: SequelAE-2.0. , 2013, , .		1
197	Repairing the Parkinsonian Brain. Journal of Parkinson's Disease, 2021, 11, S123-S125.	1.5	1
198	Somatic mosaic approaches and the aging brain. Neurobiology of Aging, 2002, 23, 977-984.	1.5	0

#	Article	IF	Citations
199	Systems biology: A primer. NeuroRx, 2006, 3, 293-294.	6.0	0
200	Potential of Nurr1 interactions to disclose new Parkinsonâ€™s therapeutics. Future Neurology, 2009, 4, 161-165.	0.9	0
201	Article Commentary: Technology and Innovation: 2010 a Year in Review. Cell Transplantation, 2011, 20, 1315-1318.	1.2	0
202	EDITORIAL: PREFACE TO THE SPECIAL SECTION. Technology and Innovation, 2012, 14, 179-179.	0.2	0
203	EDITORIAL: TECHNOLOGY, INNOVATION, AND HEALTH. Technology and Innovation, 2012, 13, 261-262.	0.2	0
204	TECHNOLOGY AND INVENTION. Technology and Innovation, 2012, 14, 1-2.	0.2	0
205	Network modeling to identify new mechanisms and therapeutic targets for Parkinsonâ€™s disease. Expert Review of Neurotherapeutics, 2013, 13, 685-693.	1.4	0
206	INTRODUCTION: NEW INSIGHTS INTO LONG-STANDING ISSUES. Technology and Innovation, 2016, 17, 85-86.	0.2	0
207	Blood Biomarkers of Cognitive Health and Neurodegenerative Disease. , 2020, , 568-586.		0
208	HSV Encoded ICP-0 Inhibits TLR Signaling in CLL Cells by Targeting TRAF-6.. Blood, 2005, 106, 2953-2953.	0.6	0
209	HSV ICP0 Inhibits TLR-Mediated NF-ÎºB Response to TLR Signaling.. Blood, 2006, 108, 5487-5487.	0.6	0
210	Regulation of TLR Signaling by USP7.. Blood, 2007, 110, 2300-2300.	0.6	0
211	EDITORIAL: THE INAUGURAL CONFERENCE OF THE NATIONAL ACADEMY OF INVENTORS. Technology and Innovation, 2012, 14, 219-220.	0.2	0